MCID: CLL004
MIFTS: 31

Cellular Myxoid Liposarcoma

Categories: Cancer diseases

Aliases & Classifications for Cellular Myxoid Liposarcoma

MalaCards integrated aliases for Cellular Myxoid Liposarcoma:

Name: Cellular Myxoid Liposarcoma 12 15
Round Cell Liposarcoma 12 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5692
NCIt 49 C4252
SNOMED-CT 67 404070007 43296007
UMLS 71 C0334471

Summaries for Cellular Myxoid Liposarcoma

MalaCards based summary : Cellular Myxoid Liposarcoma, also known as round cell liposarcoma, is related to mixed liposarcoma and soft tissue sarcoma. An important gene associated with Cellular Myxoid Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include t cells, adipocyte and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Cellular Myxoid Liposarcoma

Diseases related to Cellular Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 mixed liposarcoma 32.3 MDM2 FUS DDIT3 CDK4
2 soft tissue sarcoma 30.9 MDM2 EWSR1
3 pleomorphic lipoma 30.5 SERPINA3 MDM2 CDK4
4 lipoblastoma 30.4 MDM2 CDK4
5 myxoid liposarcoma 30.4 SSX2 SS18 MDM2 HCCS FUS EWSR1
6 liposarcoma 30.3 PIK3CA MDM2 FUS EWSR1 DDIT3 CDK4
7 spindle cell lipoma 30.3 MDM2 CDK4
8 chondrosarcoma 30.1 SERPINA3 MDM2 EWSR1 CDK4
9 extraosseous chondrosarcoma 30.0 SS18 FUS EWSR1
10 connective tissue benign neoplasm 29.8 SERPINA3 MDM2 EWSR1 CDK4
11 lipomatosis, multiple 29.8 SERPINA3 MDM2 FUS EWSR1 DDIT3 CDK4
12 chondrosarcoma, extraskeletal myxoid 29.1 SSX2 SS18 FUS EWSR1 DDIT3
13 pleomorphic liposarcoma 28.3 YEATS4 SERPINA3 MDM2 HCCS FUS EWSR1
14 myxofibrosarcoma 28.3 SSX2 SS18 SERPINA3 MDM2 FUS EWSR1
15 sarcoma, synovial 27.5 SSX2 SS18 SERPINA3 MDM2 FUS EWSR1
16 dedifferentiated liposarcoma 27.3 YEATS4 SSX2 SS18 SERPINA3 MDM2 HCCS
17 sarcoma 27.1 SSX2 SS18 SERPINA3 PIK3CA MDM2 FUS
18 well-differentiated liposarcoma 27.0 YEATS4 SSX2 SS18 SERPINA3 MDM2 HCCS
19 sclerosing liposarcoma 10.4 MDM2 FUS
20 extraskeletal chondroma 10.4 SERPINA3 EWSR1
21 extraskeletal ewing sarcoma 10.4 FUS EWSR1
22 periosteal osteogenic sarcoma 10.4 MDM2 EWSR1
23 ring chromosome 7 10.3 MDM2 CDK4
24 mediastinum liposarcoma 10.3 MDM2 CDK4
25 hereditary melanoma 10.3 MDM2 CDK4
26 fibrous histiocytoma 10.3 SERPINA3 FUS EWSR1
27 infiltrating lipoma 10.3 MDM2 CDK4
28 gastric liposarcoma 10.3 MDM2 CDK4
29 diffuse lipomatosis 10.3 MDM2 CDK4
30 liposarcoma of bone 10.3 MDM2 CDK4
31 adult liposarcoma 10.3 MDM2 CDK4
32 paratesticular lipoma 10.3 MDM2 CDK4
33 lipoma of spermatic cord 10.3 MDM2 CDK4
34 extraosseous osteosarcoma 10.2 MDM2 CDK4
35 infiltrating angiolipoma 10.2 MDM2 CDK4
36 myositis ossificans 10.2 MDM2 CDK4
37 heart cancer 10.2 SERPINA3 MDM2
38 pediatric fibrosarcoma 10.2 SERPINA3 EWSR1
39 heart sarcoma 10.2 SSX2 MDM2
40 juxtacortical osteosarcoma 10.1 MDM2 EWSR1 CDK4
41 peripheral osteosarcoma 10.1 MDM2 EWSR1 CDK4
42 spindle cell liposarcoma 10.1 MDM2 DDIT3 CDK4
43 embryonal rhabdomyosarcoma 10.1 MDM2 EWSR1 CDK4
44 ring chromosome 10.1 MDM2 EWSR1 CDK4
45 bone osteosarcoma 10.1 MDM2 EWSR1 CDK4
46 undifferentiated embryonal sarcoma of the liver 10.1 SERPINA3 MDM2 CDK4
47 familial retinoblastoma 10.1 MDM2 CDK4
48 embryonal sarcoma 10.1 SERPINA3 MDM2 CDK4
49 malignant inflammatory fibrous histiocytoma 10.1 SERPINA3 MDM2 CDK4
50 myxoid chondrosarcoma 10.1

Graphical network of the top 20 diseases related to Cellular Myxoid Liposarcoma:



Diseases related to Cellular Myxoid Liposarcoma

Symptoms & Phenotypes for Cellular Myxoid Liposarcoma

GenomeRNAi Phenotypes related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 10.31 FUS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.31 CDK4 HCCS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.31 CDK4 HCCS PIK3CA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 10.31 EWSR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 10.31 EWSR1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 10.31 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.31 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.31 PIK3CA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.31 PIK3CA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.31 HCCS PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.31 PIK3CA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.31 PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 10.31 HCCS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 10.31 CDK4
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.31 EWSR1 HCCS PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-3 10.31 FUS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.31 CDK4 HCCS PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 10.31 CDK4
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.31 PIK3CA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-52 10.31 EWSR1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.31 CDK4 EWSR1 HCCS PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 10.31 HCCS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.31 HCCS FUS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.31 FUS
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.31 FUS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-76 10.31 SSX2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.31 CDK4 EWSR1 FUS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.31 EWSR1 SSX2
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.31 EWSR1

Drugs & Therapeutics for Cellular Myxoid Liposarcoma

Drugs for Cellular Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
3
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
4
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
5
Varespladib methyl Investigational Phase 2 172733-08-3
6 Gastrointestinal Agents Phase 2
7 Hormones Phase 2
8 Antineoplastic Agents, Hormonal Phase 2
9 Antiemetics Phase 2
10 Hormone Antagonists Phase 2
11 glucocorticoids Phase 2
12 Anti-Inflammatory Agents Phase 2
13
Calcium carbonate Approved, Investigational Phase 1 471-34-1
14
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
15 Antiviral Agents Phase 1
16 Anti-Infective Agents Phase 1
17 Anti-HIV Agents Phase 1
18 Analgesics Phase 1
19 Interleukin-2 Phase 1
20 Analgesics, Non-Narcotic Phase 1
21 Anti-Retroviral Agents Phase 1
22
Serine Investigational, Nutraceutical Phase 1 56-45-1 5951
23 interferons Early Phase 1
24 Interferon-alpha Early Phase 1
25 Interferon-gamma Early Phase 1

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
2 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Completed NCT02609984 Phase 2
3 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
4 A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting NCT04044768 Phase 2
5 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 2
6 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
7 A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma. Completed NCT01477021 Phase 1 cyclophosphamide
8 A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Completed NCT02387125 Phase 1 Metronomic CPA
9 A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting NCT04044859 Phase 1
10 Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NYESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 for Patients With Sarcoma Recruiting NCT03450122 Phase 1 Cyclophosphamide;Immunotherapeutic Combination Product CMB305
11 A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2 Withdrawn NCT02059850 Phase 1 Cyclophosphamide
12 Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors Withdrawn NCT02210104 Phase 1 Ipilimumab;Cyclophosphamide
13 A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Terminated NCT01957709 Early Phase 1

Search NIH Clinical Center for Cellular Myxoid Liposarcoma

Genetic Tests for Cellular Myxoid Liposarcoma

Anatomical Context for Cellular Myxoid Liposarcoma

MalaCards organs/tissues related to Cellular Myxoid Liposarcoma:

40
T Cells, Adipocyte, Testes, Testis, Bone, Heart, Lymph Node

Publications for Cellular Myxoid Liposarcoma

Articles related to Cellular Myxoid Liposarcoma:

(show top 50) (show all 172)
# Title Authors PMID Year
1
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. 61
32374488 2020
2
The Utility of Perilipin in Liposarcomas: PLIN1 Differentiates Round Cell Liposarcoma From Other Round Cell Sarcomas. 61
32205741 2020
3
Early detection of multiple bone and extra-skeletal metastases by body magnetic resonance imaging (BMRI) after treatment of Myxoid/Round-Cell Liposarcoma (MRCLS). 61
31447287 2019
4
Myxoid Liposarcoma With Skeletal Metastases: Pathophysiology and Imaging Characteristics. 61
31813645 2019
5
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. 61
31171504 2019
6
CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. 61
30942427 2019
7
Dedifferentiated Liposarcoma of the Left Thigh: a Rare Case. 61
31391701 2019
8
Sarcoma Stem Cell Heterogeneity. 61
31016597 2019
9
EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review. 61
31049020 2019
10
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. 61
31170709 2019
11
A Neglected Case of Multifocal Liposarcoma Presented in Five Different Sites in a Syrian Woman: A case report. 61
31743843 2019
12
A Comparison of the Histopathologic Growth Patterns Between Non-Merkel Cell Small Round Blue Cell Tumors and Merkel Cell Carcinoma. 61
30045067 2018
13
Next frontiers in systemic therapy for soft tissue sarcoma. 61
30173533 2018
14
Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. 61
29888161 2018
15
Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas. 61
29529647 2018
16
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. 61
29280411 2018
17
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway. 61
29190494 2018
18
Myxoid-round cell liposarcoma: MRI appearance after radiation therapy and relationship to response. 61
29484077 2017
19
[Detection of fusion gene transcript in formalin-fixed paraffin-embedded myxoid/round cell liposarcoma tissues by improved reverse transcription polymerase chain reaction]. 61
29050077 2017
20
Soft tissue sarcomas: From a morphological to a molecular biological approach. 61
28759137 2017
21
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. 61
28463396 2017
22
Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies. 61
28526720 2017
23
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma. 61
28903344 2017
24
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models. 61
28494349 2017
25
Hypercellular round cell liposarcoma: A comprehensive cytomorphologic study and review of 8 cases. 61
28469314 2017
26
Case Report: An incidental finding of an metastases noted in a "cancer to cancer adrenal tumor " from a large malignant nerve sheath tumor of the thigh. 61
29862013 2017
27
Intramuscular Hibernoma of the Scapular Region Misdiagnosed on Cytology as a Malignant Lesion: A Report of a Rare Case. 61
29563939 2017
28
The role of histology, grading, location of tumour and ploidy in evaluation of outcome in patients with liposarcoma. 61
29517205 2017
29
Liposarcoma: Multimodality Management and Future Targeted Therapies. 61
27591497 2016
30
Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. 61
27495042 2016
31
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. 61
26970672 2016
32
Managing Liposarcomas: Cutting Through the Fat. 61
26962163 2016
33
Cement leakage and complication of liposarcoma spinal metastasis during vertebral augmentation procedure: a case report. 61
26911878 2016
34
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. 61
26595521 2016
35
Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. 61
27326262 2016
36
SRC inhibition represents a potential therapeutic strategy in liposarcoma. 61
26084847 2015
37
Retroperitoneal Liposarcoma: an Autopsy Case. 61
28275407 2015
38
Liposarcomas of the posterior mediastinum: clinicopathologic study of 18 cases. 61
25475695 2015
39
Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up. 61
25583234 2015
40
Application of molecular biology to individualize therapy for patients with liposarcoma. 61
25993159 2015
41
[Myxoid/round cell liposarcoma of the brachial plexus]. 61
25126709 2014
42
Mode of action of trabectedin in myxoid liposarcomas. 61
24213580 2014
43
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. 61
24457462 2014
44
Emerging therapies for adult soft tissue sarcoma. 61
24555529 2014
45
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. 61
24554062 2014
46
Equivalent cross-relaxation rate imaging positively correlates with pathological grade and cell density of adipocytic tumors. 61
24439360 2014
47
Computed tomography manifestations of histologic subtypes of retroperitoneal liposarcoma. 61
25124571 2014
48
DDIT3 Expression in Liposarcoma Development. 61
24790523 2014
49
Cell senescence in myxoid/round cell liposarcoma. 61
25093008 2014
50
Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma. 61
25393000 2014

Variations for Cellular Myxoid Liposarcoma

Expression for Cellular Myxoid Liposarcoma

Search GEO for disease gene expression data for Cellular Myxoid Liposarcoma.

Pathways for Cellular Myxoid Liposarcoma

Pathways related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.38 SSX2 SS18 MDM2 FUS EWSR1 DDIT3

GO Terms for Cellular Myxoid Liposarcoma

Biological processes related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell cycle arrest GO:0071157 8.96 MDM2 CDK4
2 tRNA threonylcarbamoyladenosine metabolic process GO:0070525 8.62 CTAG1B CTAG1A

Molecular functions related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 8.62 CLEC18C CLEC18A

Sources for Cellular Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....